BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanduleanu S, Jonkers D, De Bruïne A, Hameeteman W, Stockbrügger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 2001;15:1163-1175. [PMID: 11472319 DOI: 10.1046/j.1365-2036.2001.01029.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Choi S, Lee JG, Lee AR, Eun CS, Han DS, Park CH. Helicobacter pylori antibody and pepsinogen testing for predicting gastric microbiome abundance. PLoS One 2019;14:e0225961. [PMID: 31800638 DOI: 10.1371/journal.pone.0225961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Shin GY, Park JM, Hong J, Cho YK, Yim HW, Choi MG. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study. Am J Gastroenterol 2021;116:1211-9. [PMID: 34074826 DOI: 10.14309/ajg.0000000000001167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006;55:1217-21. [PMID: 16905689 DOI: 10.1136/gut.2005.090514] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 4.5] [Reference Citation Analysis]
4 Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: A review of the current evidence. Therap Adv Gastroenterol. 2019;12:1756284819834511. [PMID: 30886648 DOI: 10.1177/1756284819834511] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 19.5] [Reference Citation Analysis]
5 El-omar EM. Role of Host Genetic Susceptibility in the Pathogenesis of Gastric Cancer. In: Wang TC, Fox JG, Giraud AS, editors. The Biology of Gastric Cancers. New York: Springer; 2009. pp. 235-50. [DOI: 10.1007/978-0-387-69182-4_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Sanduleanu S, Bruïne ADE, Biemond I, Stridsberg M, Jonkers D, Lundqvist G, Hameeteman W, Stockbrügger RW. Ratio between serum IL-8 and pepsinogen A/C: a marker for atrophic body gastritis: Serum markers for atrophic body gastritis. European Journal of Clinical Investigation 2003;33:147-54. [DOI: 10.1046/j.1365-2362.2003.01101.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
7 Dent J, Tytgat G. Reflux disease management strategy: initial therapy: SESSION II: REFLUX DISEASE MANAGEMENT STRATEGY: INITIAL THERAPY. Alimentary Pharmacology & Therapeutics 2003;17:28-52. [DOI: 10.1046/j.1365-2036.17.s1.9_1.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
8 Del Piano M, Anderloni A, Balzarini M, Ballarè M, Carmagnola S, Montino F, Orsello M, Pagliarulo M, Tari R, Soattini L, Sforza F, Mogna L, Mogna G. The Innovative Potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to Restore the “Gastric Barrier Effect” in Patients Chronically Treated With PPI: A Pilot Study. Journal of Clinical Gastroenterology 2012;46:S18-26. [DOI: 10.1097/mcg.0b013e318267b55d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
9 Tran-duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016;14:1706-1719.e5. [DOI: 10.1016/j.cgh.2016.05.018] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 17.6] [Reference Citation Analysis]
10 El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, Chow WH. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124:1193-1201. [PMID: 12730860 DOI: 10.1016/s0016-5085(03)00157-4] [Cited by in Crossref: 631] [Cited by in F6Publishing: 272] [Article Influence: 35.1] [Reference Citation Analysis]
11 Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology. 2008;134:306-323. [PMID: 18166359 DOI: 10.1053/j.gastro.2007.11.009] [Cited by in Crossref: 345] [Cited by in F6Publishing: 340] [Article Influence: 26.5] [Reference Citation Analysis]
12 Hold GL, El-Omar EM. Genetic aspects of inflammation and cancer. Biochem J. 2008;410:225-235. [PMID: 18254728 DOI: 10.1042/bj20071341] [Cited by in Crossref: 74] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
13 Pohl D, Fox M, Fried M, Göke B, Prinz C, Mönnikes H, Rogler G, Dauer M, Keller J, Lippl F, Schiefke I, Seidler U, Allescher HD; Kandahar Study Group. Do we need gastric acid? Digestion 2008;77:184-97. [PMID: 18594142 DOI: 10.1159/000142726] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
14 El–omar EM, Chow W, Rabkin CS. Gastric cancer and H. pylori: Host genetics open the way. Gastroenterology 2001;121:1002-4. [DOI: 10.1053/gast.2001.28739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Kim EJ, Baik GH. Review on Gastric Mucosal Microbiota Profiling Differences in Patients with Chronic Gastritis, Intestinal Metaplasia, and Gastric Cancer. Korean J Gastroenterol 2014;64:390. [DOI: 10.4166/kjg.2014.64.6.390] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
16 Lundell L, Havu N, Miettinen P, Myrvold HE, Wallin L, Julkunen R, Levander K, Hatlebakk JG, Liedman B, Lamm M, Malm A, Walan A; Nordic Gerd Study Group. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006;23:639-647. [PMID: 16480403 DOI: 10.1111/j.1365-2036.2006.02792.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
17 Hu Y, He LH, Xiao D, Liu GD, Gu YX, Tao XX, Zhang JZ. Bacterial flora concurrent with Helicobacter pylori in the stomach of patients with upper gastrointestinal diseases. World J Gastroenterol 2012; 18(11): 1257-1261 [PMID: 22468090 DOI: 10.3748/wjg.v18.i11.1257] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
18 Jiang K, Jiang X, Wen Y, Liao L, Liu F. Relationship between long‐term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. Journal of Gastroenterology and Hepatology 2019;34:1898-905. [DOI: 10.1111/jgh.14759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
19 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 73] [Article Influence: 24.0] [Reference Citation Analysis]
20 Kulkarni G, Gohil K, Misra V, Kakrani AL, Misra SP, Patole M, Shouche Y, Dharne M. Multilocus sequence typing of Ochrobactrum spp. isolated from gastric niche. J Infect Public Health 2017;10:201-10. [PMID: 27287730 DOI: 10.1016/j.jiph.2016.04.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
21 Park CH, Lee JG, Lee AR, Eun CS, Han DS. Network construction of gastric microbiome and organization of microbial modules associated with gastric carcinogenesis. Sci Rep 2019;9:12444. [PMID: 31455798 DOI: 10.1038/s41598-019-48925-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
22 Hu Y, He LH, Xiao D, Liu GD, Gu YX, Tao XX, Zhang JZ. Bacterial flora concurrent with Helicobacter pylori in the stomach of patients with upper gastrointestinal diseases. World J Gastroenterol. 2012;18:1257-1261. [PMID: 22468090 DOI: 10.374/wjg.v18.i11.1257] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Tozun N, Vardareli E. Gut Microbiome and Gastrointestinal Cancer: Les liaisons Dangereuses. Journal of clinical gastroenterology. 2016;50:S191-S196. [PMID: 27741173 DOI: 10.1097/mcg.0000000000000714] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
24 Gisbert JP, Piqué JM. Indicaciones y consecuencias de la erradicación de Helicobacter pylori en la enfermedad por reflujo gastroesofágico. Medicina Clínica 2005;124:697-709. [DOI: 10.1157/13075094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014;CD010623. [PMID: 25464111 DOI: 10.1002/14651858.cd010623.pub2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
26 Ko Y, Tang J, Sanagapalli S, Kim BS, Leong RW. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms. Expert Opin Drug Saf. 2016;15:53-63. [PMID: 26560097 DOI: 10.1517/14740338.2016.1118050] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
27 Guo C, Liu F, Zhu L, Wu F, Cui G, Xiong Y, Wang Q, Yin L, Wang C, Wang H, Wu X, Zhang Z, Chen Z. Analysis of culturable microbiota present in the stomach of children with gastric symptoms. Braz J Microbiol 2019;50:107-15. [PMID: 30637659 DOI: 10.1007/s42770-018-0030-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sohn SH, Kim N, Jo HJ, Kim J, Park JH, Nam RH, Seok YJ, Kim YR, Lee DH. Analysis of Gastric Body Microbiota by Pyrosequencing: Possible Role of Bacteria Other Than Helicobacter pylori in the Gastric Carcinogenesis. J Cancer Prev. 2017;22:115-125. [PMID: 28698866 DOI: 10.15430/jcp.2017.22.2.115] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
29 Pinzon-Guzman C, Meyer AR, Wise R, Choi E, Muthupalani S, Wang TC, Fox JG, Goldenring JR. Evaluation of Lineage Changes in the Gastric Mucosa Following Infection With Helicobacter pylori and Specified Intestinal Flora in INS-GAS Mice. J Histochem Cytochem 2019;67:53-63. [PMID: 29969055 DOI: 10.1369/0022155418785621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Sung J, Kim N, Kim J, Jo HJ, Park JH, Nam RH, Seok YJ, Kim YR, Lee DH, Jung HC. Comparison of Gastric Microbiota Between Gastric Juice and Mucosa by Next Generation Sequencing Method. J Cancer Prev. 2016;21:60-65. [PMID: 27051651 DOI: 10.15430/jcp.2016.21.1.60] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
31 Lu DY, Tang CH, Chang CH, Maa MC, Fang SH, Hsu YM, Lin YH, Lin CJ, Lee WC, Lin HJ, Lee CH, Lai CH. Helicobacter pylori attenuates lipopolysaccharide-induced nitric oxide production by murine macrophages. Innate Immun 2012;18:406-17. [PMID: 21926162 DOI: 10.1177/1753425911413164] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
32 Engstrand L, Lindberg M. Helicobacter pylori and the gastric microbiota. Best Pract Res Clin Gastroenterol. 2013;27:39-45. [PMID: 23768551 DOI: 10.1016/j.bpg.2013.03.016] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 10.9] [Reference Citation Analysis]
33 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
34 Shin CM, Kim N, Park JH, Lee DH. Changes in Gastric Corpus Microbiota With Age and After Helicobacter pylori Eradication: A Long-Term Follow-Up Study. Front Microbiol 2020;11:621879. [PMID: 33633697 DOI: 10.3389/fmicb.2020.621879] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
35 Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903. [PMID: 19786155 DOI: 10.1016/j.amjmed.2009.04.014] [Cited by in Crossref: 114] [Cited by in F6Publishing: 94] [Article Influence: 9.5] [Reference Citation Analysis]
36 Wang ZK, Yang YS. Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol 2013; 19(10): 1541-1550 [PMID: 23539678 DOI: 10.3748/wjg.v19.i10.1541] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
37 Snaith A, El-Omar EM. Helicobacter pylori: host genetics and disease outcomes. Expert Rev Gastroenterol Hepatol. 2008;2:577-585. [PMID: 19072405 DOI: 10.1586/17474124.2.4.577] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
38 Tian G, Wu C, Li J, Liang B, Zhang F, Fan X, Li Z, Wang Y, Li Z, Liu D, Lai-Han Leung E, Chen J. Network pharmacology based investigation into the effect and mechanism of Modified Sijunzi Decoction against the subtypes of chronic atrophic gastritis. Pharmacol Res 2019;144:158-66. [PMID: 30991106 DOI: 10.1016/j.phrs.2019.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
39 Sjöstedt Zsigmond C, Hannestad U, Franzén L, Söderholm JD, Borch K. Atrophic gastritis is associated with increased sucrose permeability related to chronic inflammation. Digestion. 2005;72:201-206. [PMID: 16244483 DOI: 10.1159/000089145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
40 Kulkarni GJ, Shetty S, Dharne MS, Shouche YS. Genome sequencing analysis reveals virulence-related gene content of Ochrobactrum intermedium strain 229E, a urease-positive strain isolated from the human gastric niche. FEMS Microbiol Lett 2014;359:12-5. [PMID: 25312622 DOI: 10.1111/1574-6968.12549] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
41 Zhang X, Zhong R, Zhang Z, Yuan J, Liu L, Wang Y, Kadlubar S, Feng F, Miao X. Interaction of cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer. Mol Carcinog. 2011;50:876-883. [PMID: 21538574 DOI: 10.1002/mc.20784] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
42 Sugano K. Premalignant conditions of gastric cancer: Gastric precancerous conditions. J Gastroenterol Hepatol 2013;28:906-11. [DOI: 10.1111/jgh.12209] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
43 Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020;51:505-526. [PMID: 31990420 DOI: 10.1111/apt.15604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
44 El-Omar EM, Ng MT, Hold GL. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008;27:244-52. [PMID: 18176606 DOI: 10.1038/sj.onc.1210912] [Cited by in Crossref: 159] [Cited by in F6Publishing: 140] [Article Influence: 12.2] [Reference Citation Analysis]
45 El-omar EM. Role of host genes in sporadic gastric cancer. Best Practice & Research Clinical Gastroenterology 2006;20:675-86. [DOI: 10.1016/j.bpg.2006.04.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
46 Kanbay M, Kanbay A, Boyacioglu S. Helicobacter pylori infection as a possible risk factor for respiratory system disease: a review of the literature. Respir Med 2007;101:203-9. [PMID: 16759841 DOI: 10.1016/j.rmed.2006.04.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
47 Ubukata H, Nagata H, Tabuchi T, Konishi S, Kasuga T, Tabuchi T. Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer. Gastric Cancer. 2011;14:4-12. [PMID: 21249411 DOI: 10.1007/s10120-011-0005-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
48 Varbanova M, Schulz C, Malfertheiner P. <i>Helicobacter pylori</i> and Other Gastric Bacteria. Dig Dis 2011;29:562-9. [DOI: 10.1159/000332989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Nam SY, Jeon SW, Lee HS, Kwon YH, Park H, Choi JW. Long-term follow-up of pepsinogen I/II ratio after eradication of Helicobacter pylori in patients who underwent endoscopic mucosal resection for gastric cancer. Digestive and Liver Disease 2017;49:500-6. [DOI: 10.1016/j.dld.2016.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
50 Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety 2018;17:785-94. [DOI: 10.1080/14740338.2018.1497155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
51 Bazzoli F, Bianchi Porro G, Bianchi MG, Molteni M, Pazzato P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis. 2002;34:70-83. [PMID: 11926576 DOI: 10.1016/s1590-8658(02)80062-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
52 Miyata N, Hayashi Y, Hayashi S, Sato K, Hirai Y, Yamamoto H, Sugano K. Lipopolysaccharides From Non-Helicobacter pylori Gastric Bacteria Potently Stimulate Interleukin-8 Production in Gastric Epithelial Cells. Clin Transl Gastroenterol 2019;10:e00024. [PMID: 30913125 DOI: 10.14309/ctg.0000000000000024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22 Suppl 1:55-63. [PMID: 16042660 DOI: 10.1111/j.1365-2036.2005.02611.x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 6.5] [Reference Citation Analysis]
54 Jo HJ, Kim J, Kim N, Park JH, Nam RH, Seok YJ, Kim YR, Kim JS, Kim JM, Kim JM, Lee DH, Jung HC. Analysis of Gastric Microbiota by Pyrosequencing: Minor Role of Bacteria Other Than Helicobacter pylori in the Gastric Carcinogenesis. Helicobacter. 2016;21:364-374. [PMID: 26915731 DOI: 10.1111/hel.12293] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 10.4] [Reference Citation Analysis]
55 Russo F, Linsalata M, Orlando A. Probiotics against neoplastic transformation of gastric mucosa: Effects on cell proliferation and polyamine metabolism. World J Gastroenterol 2014; 20(37): 13258-13272 [PMID: 25309063 DOI: 10.3748/wjg.v20.i37.13258] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
56 Schulz C, Koch N, Schütte K, Pieper DH, Malfertheiner P. H. pylori and its modulation of gastrointestinal microbiota: H. pylori and other microbiota. Journal of Digestive Diseases 2015;16:109-17. [DOI: 10.1111/1751-2980.12233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
57 Yang I, Nell S, Suerbaum S. Survival in hostile territory: the microbiota of the stomach. FEMS Microbiol Rev 2013;37:736-61. [DOI: 10.1111/1574-6976.12027] [Cited by in Crossref: 90] [Cited by in F6Publishing: 69] [Article Influence: 11.3] [Reference Citation Analysis]